-
1.
公开(公告)号:US20130280301A1
公开(公告)日:2013-10-24
申请号:US13936201
申请日:2013-07-07
申请人: AMBRX, INC.
发明人: Feng TIAN , Brad HEHLI
IPC分类号: A61K39/108
CPC分类号: C12N15/70 , A61K39/0258 , C12N1/36 , C12N9/93
摘要: Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.
摘要翻译: 制备疫苗的组合物和方法,包括通过使用非天然的,非天然的或非天然编码的氨基酸使整个生物体疫苗具有有限的复制能力,从而增加疫苗安全性和功效的方法。
-
公开(公告)号:US20220226488A1
公开(公告)日:2022-07-21
申请号:US17429911
申请日:2020-02-12
申请人: Ambrx, Inc.
发明人: Sung-Ju MOON , Brian LEON , Mingchao KANG , Nickolas KNUDSEN , Jianing WANG , Sukumar SAKAMURI , Feng TIAN
IPC分类号: A61K47/68 , A61P37/04 , A61P35/00 , C07D471/04 , C07D471/14 , C07D473/18 , C07D473/34 , C07D487/04 , C07D487/14 , C07D519/00
摘要: Disclosed herein are Trastuzumab-linked TLR-agonist derivative analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The Trastuzumab-linked TLR-agonist derivative analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such Trastuzumab-linked TLR-agonist derivative analogs. Typically, the modified Trastuzumab-linked TLR-agonist derivative analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs and modified non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs, including therapeutic, diagnostic, and other biotechnology use.
-
公开(公告)号:US20240350835A1
公开(公告)日:2024-10-24
申请号:US18761130
申请日:2024-07-01
申请人: Ambrx, Inc.
发明人: Shivarupam BHOWMIK , Jianing WANG , Jinming XIA , William BRADY , Feng TIAN
CPC分类号: A61P35/00 , A61K47/68031 , C07K16/3069 , A61K45/06
摘要: The invention relates to prostate specific membrane antigen antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.
-
公开(公告)号:US20140045259A1
公开(公告)日:2014-02-13
申请号:US13851911
申请日:2013-03-27
申请人: AMBRX, INC.
发明人: Feng TIAN , Thea NORMAN , Stephanie CHU
IPC分类号: C12N15/85
摘要: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA's/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided.
摘要翻译: 本发明提供用于生产翻译成分的组合物和方法,其扩展脊椎动物细胞中遗传编码氨基酸的数目。 组分包括正交tRNA,正交氨酰-tRNA合成酶,tRNA /合成酶和非天然氨基酸的正交对。 还提供了在脊椎动物细胞中产生具有非天然氨基酸的蛋白质的蛋白质和方法。
-
5.
公开(公告)号:US20240167044A1
公开(公告)日:2024-05-23
申请号:US18506836
申请日:2023-11-10
申请人: Ambrx, Inc.
发明人: Sigeng CHEN , Yingchun LU , Feng TIAN
CPC分类号: C12N15/67 , C12N5/10 , C12N15/11 , C12N2310/20 , C12N2501/48 , C12N2510/02
摘要: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.
-
公开(公告)号:US20170096696A1
公开(公告)日:2017-04-06
申请号:US14820318
申请日:2015-08-06
申请人: AMBRX, INC.
发明人: Feng TIAN , Thea NORMAN , Stephanie CHU
IPC分类号: C12P21/02
摘要: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA's/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided. The present invention provides vertebrate cells with translation components, e.g., pairs of orthogonal aminoacyl-tRNA synthetases (O-RSs) and orthogonal tRNA's (O-tRNA's) and individual components thereof, that are used in vertebrate protein biosynthetic machinery to incorporate an unnatural amino acid in a growing polypeptide chain, in a vertebrate cell.
-
公开(公告)号:US20160024166A1
公开(公告)日:2016-01-28
申请号:US14854819
申请日:2015-09-15
申请人: Ambrx, Inc. , Eli Lilly and Company
发明人: Feng TIAN , Anna-Maria A. HAYS PUTNAM , Frank SONG , Stephanie CHU , Joseph SHEFFER , Richard S. BARNETT , Marc SILADI , Kyle ATKINSON , Darin LEE , Peter C. CANNING
IPC分类号: C07K14/505 , A61K47/48 , A61K38/18
CPC分类号: C07K14/505 , A61K38/00 , A61K38/1816 , A61K47/60 , C12N15/102
摘要: Modified animal erythropoietin polypeptides and uses thereof are provided.
摘要翻译: 提供了改良的动物促红细胞生成素多肽及其用途。
-
公开(公告)号:US20130323821A1
公开(公告)日:2013-12-05
申请号:US13963376
申请日:2013-08-09
申请人: Ambrx, Inc.
发明人: Feng TIAN , Brad HEHLI
IPC分类号: C12N15/70
CPC分类号: C12N15/70 , A61K39/0258 , C12N1/36 , C12N9/93
摘要: Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.
-
公开(公告)号:US20230226152A1
公开(公告)日:2023-07-20
申请号:US17930319
申请日:2022-09-07
申请人: Ambrx, Inc.
发明人: Sigeng CHEN , Yingchun LU , Md Harunur RASHID , Nickolas KNUDSEN , Feng TIAN
CPC分类号: A61K38/2013 , A61K47/10 , A61P35/00
摘要: The present invention provides compositions and methods comprising interleukin-2 (TL-2) polypeptide conjugates. Also described are IL-2 conjugates for the treatment of diseases or conditions including cancer.
-
10.
公开(公告)号:US20210017527A1
公开(公告)日:2021-01-21
申请号:US16958152
申请日:2018-06-02
申请人: Ambrx, Inc.
发明人: Sigeng Chen , Yingchun LU , Feng TIAN
摘要: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.
-
-
-
-
-
-
-
-
-